Childhood cancers trials in Canada

In Canada 154 Also abroad 2457

154 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Asciminib Roll-over Study
Where
Montreal
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
No phaseTaking people
Pediatric Orthopaedic Implant Safety & Efficacy
Where
Vancouver
Age
0 years to 25 years
People
4,000
Run by
University of British Columbia
See details and how to joinNCT05361980
Phase 1/2Taking people
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Where
Edmonton, Ottawa, Toronto, Vancouver
Age
12 years and over
People
840 worldwide
Run by
Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00
Phase 3Taking people
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Where
Toronto
People
200 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00
Phase 3Taking people
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Where
Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
5 years to 60 years
People
1,875 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT05675410
Phase 1/2Taking people
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Where
Toronto
Age
2 years to 30 years
People
60 worldwide
Run by
Jazz Pharmaceuticals
See details and how to joinNCT05734066
Phase 1/2Taking people
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Where
Montreal, Toronto, Vancouver
Age
2 years and over
People
420 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00
No phaseNot yet taking people in Canada
Positioning in RT - Supine vs. Upright
Where
Toronto
Age
3 years and over
People
105
Run by
University Health Network, Toronto
See details and how to joinNCT07765069
Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Toronto
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Calgary, Toronto
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 2/3Taking people
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Where
Calgary, Hamilton, Montreal, Toronto, Vancouver
People
1,541 worldwide
Run by
Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00
Early phase 1Taking people
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Where
Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
Up to 6 years
People
15
Run by
C17 Council
See details and how to joinNCT06942039
Phase 3Taking people
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Where
Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, St. John's, Toronto, Vancouver, Winnipeg
Age
Up to 30 years
People
478 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06172296
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Calgary, Montreal, Toronto
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Toronto
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
No phaseTaking people
Met Non Small Cell Cancer Registry (MOMENT)
Where
Ottawa, Québec, Toronto, Vancouver
People
700 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT05376891
Phase 2Not yet taking people in Canada
Adaptive Radiotherapy for Safe Hypofractionation
Where
Montreal
People
264
Run by
Centre hospitalier de l'Université de Montréal (CHUM)
See details and how to joinNCT07516210
Phase 1Taking people
Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
Where
Montreal, Toronto
Age
12 years and over
People
464 worldwide
Run by
Debiopharm International SA
See details and how to joinNCT04855656 · EU 2023-510063-35-00
No phaseTaking people
Collection of Tissue Samples for Cancer Research
Where
Toronto
Age
2 months and over
People
5,000 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT00900198
Phase 2Taking people
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Where
Calgary, Edmonton, Halifax, Hamilton, Montreal, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
366 days to 46 years
People
222 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06124157
Phase 2Taking people
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
Where
Montreal, Toronto
Age
12 months to 39 years
People
60 worldwide
Run by
Nationwide Children's Hospital
See details and how to joinNCT06838676
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Montreal, Toronto
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
London, Montreal, Toronto
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Where
Calgary, Toronto
People
115 worldwide
Run by
Pierre Fabre Medicament
See details and how to joinNCT03394365 · EU 2024-516622-57-00
Phase 1Taking people
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Where
Calgary, Montreal, Ottawa, Toronto
Age
15 years and over
People
30
Run by
Canadian Cancer Trials Group
See details and how to joinNCT07297667